We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

This new manual sets out the foundations for the HealthTech programme following the first part of our transformation to be simpler, relevant and purpose-led. It is the first step in an ongoing ...

More innovative healthcare technologies could soon be adopted by the NHS under reforms proposed today by NICE. The changes aim to transform how medical devices, diagnostics and digital and AI health ...

A list of downloadable documents created during development.

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the elacestrant being ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. We have a new way of making ...

There is a commercial access agreement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] ...

Use intravascular lithotripsy as an option to treat calcified coronary arteries during percutaneous coronary intervention with standard arrangements in place for clinical governance, consent and audit ...